{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:42:37Z","timestamp":1773290557698,"version":"3.50.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.thromres.2024.109064","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:06:26Z","timestamp":1718323586000},"page":"109064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Liver health in hemophilia in the era of gene therapy"],"prefix":"10.1016","volume":"240","author":[{"given":"Yesim","family":"Dargaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Levrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Lienhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.thromres.2024.109064_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/hae.12996","article-title":"Medical co-morbidities of patients with haemophilia: pain, obesity and hepatitis C","volume":"22","author":"Witkop","year":"2016","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/17474086.2021.1924054","article-title":"Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia","volume":"14","author":"De la Corte-Rodriguez","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.thromres.2024.109064_bb0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2147\/JBM.S84848","article-title":"Strategies to encourage physical activity in patients with hemophilia to improve quality of life","volume":"7","author":"Goto","year":"2016","journal-title":"J Blood Med."},{"issue":"12","key":"10.1016\/j.thromres.2024.109064_bb0020","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.thromres.2024.109064_bb0025","doi-asserted-by":"crossref","unstructured":"-Kennedy M, O' Mahony B, Roche S, McGowan M, Singleton E, Ryan K, O' Connell NM, Pipe SW, Lavin M, O' Donnell JS, Turecek PL, Gormley J; on behalf of the iPATH study group.Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study. Eur. J. Haematol. 2022 Jun;108(6):518\u2013527.","DOI":"10.1111\/ejh.13763"},{"issue":"10319","key":"10.1016\/j.thromres.2024.109064_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.109064_bb0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.15189","article-title":"Mortality in congenital hemophilia A - a systematic literature review","volume":"19","author":"Hay","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2024.109064_bb0040","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/jth.15424","article-title":"Gouw SC Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019","volume":"19","author":"Hassan","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.109064_bb0045","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/hae.14029","article-title":"Real-world analysis of haemophilia patients in China: a single centre\u2019s experience","volume":"26","author":"Song","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2024.109064_bb0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bjh.17438","article-title":"Viral hepatitis in haemophilia: historical perspective and current management","volume":"195","author":"Isfordink","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.109064_bb0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2516.2010.02388.x","article-title":"The prevalence of significant liver fibrosis and cirrhosis in haemophilia patients infected with hepatitis C using FibroScan","volume":"17","author":"Kitson","year":"2011","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0060","first-page":"1584","article-title":"End-stage liver disease in persons with hemophilia and transfusion-associated infections","volume":"100","author":"Goedert","year":"2002","journal-title":"Blood"},{"issue":"Suppl. 4","key":"10.1016\/j.thromres.2024.109064_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2516.2012.02854.x","article-title":"New approaches to the management of hepatitis C in haemophilia in 2012","volume":"18","author":"Zoulim","year":"2012","journal-title":"Haemophilia"},{"issue":"Suppl. 4","key":"10.1016\/j.thromres.2024.109064_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2516.2012.02826.x","article-title":"Treatment of human immuno-deficiency virus and hepatitis B virus infections","volume":"18","author":"Zoulim","year":"2012","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.thromres.2024.109064_bb0075","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2020.01.014","article-title":"ESCMID Study Group for Viral Hepatitis (ESGVH). Elimination of hepatitis C in Europe: can WHO targets be achieved?","volume":"26","author":"Mati\u010di\u010d","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0080","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/liv.14337","article-title":"High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: a multicenter study","volume":"40","author":"Mancuso","year":"2020","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.thromres.2024.109064_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12616","article-title":"Hepatitis C virus in hemophilia: health-related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study","volume":"5","author":"Isfordink","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0090","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/jcm11051451","article-title":"Low incidence of hepatocellular carcinoma after antiviral therapy in patients with chronic hepatitis C and hemophilia","volume":"11","author":"Kim","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.thromres.2024.109064_bb0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/hae.14668","article-title":"Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders","volume":"29","author":"Isfordink","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.109064_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejim.2021.05.033","article-title":"Diagnosis of hepatitis C-related liver disease in patients with mild hemophilia","volume":"91","author":"Krumb","year":"2021","journal-title":"Eur. J. Intern. Med."},{"issue":"10179","key":"10.1016\/j.thromres.2024.109064_bb0105","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2024.109064_bb0110","unstructured":"-EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. J Hepatol. 2017 Aug;67(2):370\u2013398."},{"issue":"2","key":"10.1016\/j.thromres.2024.109064_bb0115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2516.2008.01954.x","article-title":"Hepatitis A and B immunization for individuals with inherited bleeding disorders","volume":"15","author":"Steele","year":"2009","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2024.109064_bb0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.109064_bb0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/liv.15389","article-title":"Bulevirtide for patients with compensated chronic hepatitis delta: a review","volume":"43","author":"Degasperi","year":"2023","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0130","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.thromres.2024.109064_bb0135","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2024.109064_bb0140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2024.109064_bb0145","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.15673","article-title":"Modelling NAFLD disease burden in four Asian regions: 2019-2030","volume":"51","author":"Estes","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0150","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.thromres.2024.109064_bb0155","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3350\/cmh.2023.0004","article-title":"Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis","volume":"29","author":"Wong","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"10.1016\/j.thromres.2024.109064_bb0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/biomedicines10020249","article-title":"Hypercoagulability in patients with non-alcoholic fatty liver disease (NAFLD): causes and consequences","volume":"10","author":"Tripodi","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.thromres.2024.109064_bb0165","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2516.2010.02477.x","article-title":"The changing face of hepatitis in boys with haemophilia associated with increased prevalence of obesity","volume":"17","author":"Revel-Vilk","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.109064_bb0170","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221128294","article-title":"Prevalence of non-alcoholic fatty liver disease and associated factors in patients with moderate or severe hemophilia: a multicenter-based study","volume":"28","author":"Shen","year":"2022","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"12","key":"10.1016\/j.thromres.2024.109064_bb0175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40266-017-0500-8","article-title":"Management of hemophilia in older patients","volume":"34","author":"Franchini","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.thromres.2024.109064_bb0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2015.12.009","article-title":"Epidemiology of hepatocellular carcinoma (HCC) in hemophilia","volume":"99","author":"Shetty","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0185","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2024.109064_bb0190","doi-asserted-by":"crossref","unstructured":"-Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, Mannucci PM; Study Group of the Association of Italian Hemophilia Centers. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003Jul 1;102(1):78\u201382.","DOI":"10.1182\/blood-2002-10-3310"},{"issue":"10","key":"10.1016\/j.thromres.2024.109064_bb0195","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/MEG.0000000000002628","article-title":"Clinical course and prognosis of patients with hepatocellular carcinoma and haemophilia","volume":"35","author":"Matsuda","year":"2023","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0200","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V69.6.1721.1721","article-title":"Liver transplantation in hemophilia A","volume":"69","author":"Bontempo","year":"1987","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2024.109064_bb0205","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1111\/hae.12877","article-title":"Outcome of liver transplantation in patients with hereditary bleeding disorders: a single centre UK experience","volume":"22","author":"Murthy","year":"2016","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0210","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2141.2004.04968.x","article-title":"Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus","volume":"125","author":"Stieltjes","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0215","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2516.2007.01515.x","article-title":"Feasibility, safety and cost-effectiveness of transjugular liver biopsy following major surgery in patients with haemophilia","volume":"13","author":"Detrait","year":"2007","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0220","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0225","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2516.2005.01147.x","article-title":"Haemobilia after transjugular liver biopsy in a patient with severe haemophilia","volume":"11","author":"Kruse-Jarres","year":"2005","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0230","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on hepatology practice: past, present and future","volume":"76","author":"Anstee","year":"2022","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.thromres.2024.109064_bb0235","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0033-1354421","article-title":"Noninvasive assessment of liver fibrosis in patients with chronic hepatitis C (and congenital bleeding disorders): where do we stand?","volume":"39","author":"Coppola","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.109064_bb0240","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2516.2009.02092.x","article-title":"Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C","volume":"16","author":"Maor","year":"2010","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0245","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1365-2516.2010.02204.x","article-title":"Correlation of transient elastography with APRI and FIB-4 in a cohort of patients with congenital bleeding disorders and HCV or HIV\/HCV coinfection","volume":"16","author":"Vidovic","year":"2010","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2024.109064_bb0250","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0255","doi-asserted-by":"crossref","DOI":"10.1148\/rg.220181","article-title":"Liver fibrosis, fat, and iron evaluation with MRI and fibrosis and fat evaluation with US: a practical guide for radiologists","volume":"43","author":"Guglielmo","year":"2023","journal-title":"Radiographics"},{"issue":"20","key":"10.1016\/j.thromres.2024.109064_bb0260","doi-asserted-by":"crossref","first-page":"10497","DOI":"10.1128\/JVI.76.20.10497-10502.2002","article-title":"Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector","volume":"76","author":"Mingozzi","year":"2002","journal-title":"J. Virol."},{"issue":"7\u20138","key":"10.1016\/j.thromres.2024.109064_bb0265","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum. Gene Ther."},{"issue":"12","key":"10.1016\/j.thromres.2024.109064_bb0270","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/ph5121372","article-title":"The liver as a target organ for GT: state of the art, challenges, and future perspectives","volume":"5","author":"Jacobs","year":"2012","journal-title":"Pharmaceuticals (Basel)"},{"issue":"26","key":"10.1016\/j.thromres.2024.109064_bb0275","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.109064_bb0280","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"GENEr8-1 Trial Group. Valoctocogene Roxaparvovec gene therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2024.109064_bb0285","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.109064_bb0290","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2024.109064_bb0295","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.thromres.2024.109064_bb0300","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2024.109064_bb0305","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/mt.2013.218","article-title":"CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors\u2019 genome","volume":"22","author":"Wu","year":"2014","journal-title":"Mol. Ther."},{"issue":"25","key":"10.1016\/j.thromres.2024.109064_bb0310","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109064_bb0315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omtm.2019.11.007","article-title":"Prednisolone does not regulate factor VIII expression in mice receiving AAV5-hFVIII-SQ: valoctocogene roxaparvovec","volume":"17","author":"Zhang","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"8","key":"10.1016\/j.thromres.2024.109064_bb0320","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.thromres.2024.109064_bb0325","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2024.109064_bb0330","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3324\/haematol.2015.129858","article-title":"The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for haemophilia A","volume":"100","author":"Arruda","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.thromres.2024.109064_bb0335","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.jtha.2023.10.005","article-title":"Cellular stress and coagulation factor production: when more is not necessarily better","volume":"21","author":"Chen","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109064_bb0340","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1016\/j.thromres.2024.109064_bb0345","author":"European Medicines Agency"},{"key":"10.1016\/j.thromres.2024.109064_bb0350","author":"European Medicines Agency"},{"issue":"10386","key":"10.1016\/j.thromres.2024.109064_bb0355","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0360","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.14607","article-title":"Prevalence and risk factors for hepato- cellular carcinoma in individuals with haemophilia in the era of direct-acting antiviral agents: a national inpatient sample study","volume":"28","author":"Yang","year":"2022","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2024.109064_bb0365","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cld.2023.06.004","article-title":"Diagnosis of autoimmune hepatitis","volume":"28","author":"Flikshteyn","year":"2024","journal-title":"Clin. Liver Dis."},{"issue":"3","key":"10.1016\/j.thromres.2024.109064_bb0370","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1684\/hma.2023.1779","article-title":"Mod\u00e8le Hub & Spoke en France: organisation des soins et parcours des patients pour la th\u00e9rapie g\u00e9nique de l\u2019h\u00e9mophilie","volume":"29","author":"Dargaud","year":"2023","journal-title":"H\u00e9matologie"},{"key":"10.1016\/j.thromres.2024.109064_bb0375","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.amjmed.2023.10.022","article-title":"The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review","volume":"137","author":"Ma","year":"2024","journal-title":"Am J Med."},{"issue":"18","key":"10.1016\/j.thromres.2024.109064_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810228","article-title":"The arrival of gene therapy for patients with hemophilia A","volume":"23","author":"Castaman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.thromres.2024.109064_bb0385","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40259-023-00615-4","article-title":"Evaluating gene therapy as a potential paradigm shift in treating severe hemophilia","volume":"37","author":"Thornburg","year":"2023","journal-title":"BioDrugs"},{"issue":"11","key":"10.1016\/j.thromres.2024.109064_bb0390","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1111\/jth.15023","article-title":"Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH","volume":"18","author":"Konkle","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.109064_bb0395","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/hae.14912","article-title":"Landmark endorsement of a global registry: the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), publicly endorses World Federation of Hemophilia gene therapy Registry as global standard","volume":"30","author":"Konkle","year":"2024","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2024.109064_bb0400","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"25","key":"10.1016\/j.thromres.2024.109064_bb0405","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood.2021014735","article-title":"Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A","volume":"140","author":"Batty","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2024.109064_bb0410","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/hum.2016.002","article-title":"AAV2 and hepatocellular carcinoma","volume":"27","author":"Nault","year":"2016","journal-title":"Hum. Gene Ther."},{"issue":"4","key":"10.1016\/j.thromres.2024.109064_bb0415","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno-associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella","year":"2020","journal-title":"Gut"},{"issue":"17","key":"10.1016\/j.thromres.2024.109064_bb0420","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.thromres.2024.109064_bb0425","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1182\/bloodadvances.2023010723","article-title":"Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy","volume":"7","author":"La Mura","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2024.109064_bb0430","doi-asserted-by":"crossref","unstructured":"-Kasimsetty A, Sabatino DE. Integration and the risk of liver cancer \u2013 is there a real risk ? J Viral Hepat 2024; Apr 31 Suppl 1:26\u201334.","DOI":"10.1111\/jvh.13915"},{"issue":"12","key":"10.1016\/j.thromres.2024.109064_bb0435","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.thromres.2024.109064_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1368658","article-title":"Diving into progress: a review on current therapeutic advancements in spinal muscular atrophy","volume":"15","author":"Bagga","year":"2024","journal-title":"Front Neurol."},{"key":"10.1016\/j.thromres.2024.109064_bb0445","article-title":"GT for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for Onasemnogene Abeparvovec (Zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.thromres.2024.109064_bb0450","unstructured":"-Ismail AM, Yates B, Jayaram K, Kenet G, Mason J, Mahlangu J, Dunn AL, Shapiro S, Wang M, Peyvandi F, Giermasz A, Kazmi R, Key NS, Robinson TM, Fong S. Human liver biopsy analysis reveals lower RNA transcription may contribute to a decline in FVIII levels following AAV5-hFVIII-SQ gene therapy. European Association for Haemophilia and Allied Disorders (EAHAD) meeting 2024; SLAM session 6:OR06."},{"key":"10.1016\/j.thromres.2024.109064_bb0455","unstructured":"-Yates B. Human liver biopsy analysis shows decline in FVIII levels following AAV5-hFVIII-SQ GT may be due to low RNA transcription levels despite persistence of full-length episomal vector genomes. World Federation of Hemophilia (WFH) Congress 2024; WE-FP-09 Free Paper Session \u2013 Gene Therapy."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:03:17Z","timestamp":1720044197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":91,"alternative-id":["S0049384824001968"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109064","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver health in hemophilia in the era of gene therapy","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109064"}}